Bulletin
Investor Alert

July 26, 2021, 11:15 p.m. EDT

Acute Pancreatitis Market: Industry Analysis, Epidemiology, Pipeline Therapies, Treatment and Companies by DelveInsight| CalciMedica, Regeneron Pharmaceuticals and Others.

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Jul 26, 2021 (AB Digital via COMTEX) -- Acute pancreatitis is characterized by inflammation of the exocrine pancreas which occurs as a result of auto digestion of the pancreas by pancreatic enzymes. AP is associated with acinar cell injury and both a local and systemic inflammatory response. The incidence of acute pancreatitis has been increasing worldwide, but the major etiologies remain gallstones and alcohol.

DelveInsight's "Acute Pancreatitis Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Acute Pancreatitis, historical and forecasted epidemiology as well as the Acute Pancreatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some Key Highlights from the Acute Pancreatitis Market Report:

  • The United States accounted for the largest market size of AP i.e. USD 498.37 Million in 2020

  • According to Delveinsight’s estimates, total diagnosed incident population of AP in the 7MM was 502,390 in 2020.

  • The estimates suggest that the gender based incidence varied in the 7MM with the male incident cases higher in the United Kingdom, Japan, and Germany, whereas in the United States the female incident cases were higher.

  • In approximately 15% of cases, patient can develop severe pancreatitis with tissue damage (also called Acute Necrotizing Pancreatitis (ANP)).

  • As per a study by Vege et al., the reported annual incidence of acute pancreatitis in the United States ranges from 4.9 to 35 per 100,000 population.

  • According to a study published by Ouyang et al., 2017, the incidence of acute pancreatitis ranges from 13 to 45 per 100,000 population-years and that of chronic pancreatitis ranges from 5 to 12 per 100,000 population-years.

To gain more insights request sample @ https://www.delveinsight.com/sample-request/acute-pancreatitis-market

According to The National Pancreas Foundation, acute pancreatitis is an inflammatory condition of the pancreas that is painful and deadly. Despite the great advances in critical care medicine over the past 20 years, acute pancreatitis’ mortality rate has remained at about 10%. Diagnosis of pancreatic problems is often difficult, and treatments are delayed because the organ is relatively inaccessible.

There are no easy ways to see the pancreas directly without surgery, and available imaging studies are often inadequate. In addition to the acute form, there are hereditary and chronic forms of pancreatitis that can devastate a person over many years. Sufferers often endure pain and malnutrition and are most likely left with a higher risk of pancreatic cancer.

To gain more insights request sample @ https://www.delveinsight.com/sample-request/acute-pancreatitis-market

Some of the Acute Pancreatitis Companies:

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.